Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.

@article{Fraser2009DasatinibIR,
  title={Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.},
  author={Cara K. Fraser and Stephen J. Blake and Kerrilyn R Diener and Alan Bruce Lyons and Michael P. Brown and Timothy P Hughes and John D Hayball},
  journal={Experimental hematology},
  year={2009},
  volume={37 2},
  pages={256-65}
}
OBJECTIVE Dasatinib (BMS-354825) is a small molecule Src/Abl tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Members of the Src family of kinases are involved in the induction of innate and adaptive immunity. The purpose of this study was to evaluate the… CONTINUE READING